Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

Apr 16, 2021

SELL
$16.56 - $25.46 $41,400 - $63,650
-2,500 Closed
0 $0
Q4 2020

Feb 24, 2021

BUY
$15.77 - $19.03 $39,393 - $47,536
2,498 Added 124900.0%
2,500 $43,000
Q4 2020

Feb 23, 2021

BUY
$15.77 - $19.03 $31 - $38
2 New
2 $43,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $244M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Fort Pitt Capital Group, LLC Portfolio

Follow Fort Pitt Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fort Pitt Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fort Pitt Capital Group, LLC with notifications on news.